EMA vs FDA: Key Differences RA Teams Must Understand Early EMA vs FDA: Key Differences RA Teams Must Understand Early The regulation of pharmaceuticals and biotechnology products operates under complex and frequently changing frameworks. Within the EU and US, the EMA and FDA serve as primary regulatory bodies overseeing drug approval pathways, including clinical trials and pharmacovigilance. Understanding the nuances between these agencies is essential for Regulatory Affairs (RA), Chemistry, Manufacturing and Controls (CMC), and Labelling teams engaged in drug development and post-market surveillance. Regulatory Affairs Context Regulatory Affairs is a critical function within the pharmaceutical industry, responsible for ensuring…

Centralised Procedure: When It Is Mandatory and When It Is Strategic Centralised Procedure: When It Is Mandatory and When It Is Strategic The centralised procedure represents a key pathway for obtaining marketing authorisations in the European Union (EU). This article aims to provide a comprehensive overview of the circumstances under which the centralised procedure is mandatory or can be considered as a strategic choice. Designed for Regulatory Affairs (RA) professionals, this guide integrates regulatory expectations, documentation requirements, and decision-making processes relevant to the centralised procedure. Context of the Centralised Procedure The centralised procedure allows for the marketing authorisation of medicinal…

Decentralised vs Mutual Recognition: Choosing the Right EU Pathway Decentralised vs Mutual Recognition: Choosing the Right EU Pathway The European regulatory landscape provides multiple pathways for obtaining marketing authorisation for medicinal products. Understanding whether to engage in a Decentralised Procedure (DCP) or a Mutual Recognition Procedure (MRP) can significantly impact the speed and success of drug approvals. This article aims to provide an in-depth, structured explanation of the relevant regulations, guidelines, and agency expectations governing these pathways, specifically tailored for Regulatory Affairs (RA) professionals in the pharmaceutical and biotechnology sectors. Regulatory Context The EU regulatory environment is primarily governed by…

How EU-CTR Changes the Way You Plan and Run Clinical Trials in Europe How EU-CTR Changes the Way You Plan and Run Clinical Trials in Europe The landscape of clinical trials in Europe has undergone significant transformation with the introduction of the Clinical Trials Regulation (EU-CTR), which came into full effect on January 31, 2022. This regulation aims to streamline the approval process for clinical trials, thereby fostering innovation while ensuring robust regulatory oversight. In this article, we will explore the regulatory context, legal foundations, expected documentation, review and approval flows, as well as common deficiencies encountered in the compliance…

Structuring a High-Quality MAA for the EMA: RA Checklist Structuring a High-Quality MAA for the EMA: RA Checklist In the evolving landscape of drug development and approval, the successful submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) is paramount. Given the complexity of regulatory submissions, this guide serves as a detailed manual outlining the necessary steps, documentation, and considerations required to build a robust MAA that meets the EMA’s expectations. This article is aimed at Regulatory Affairs (RA), Chemistry, Manufacturing and Controls (CMC), and Labelling teams within pharmaceutical companies navigating the global regulatory frameworks. Context…

Managing Rapporteur, Co-Rapporteur and CHMP Interactions Effectively Managing Rapporteur, Co-Rapporteur and CHMP Interactions Effectively In the dynamic landscape of pharmaceutical development, understanding the intricacies of regulatory interactions is paramount to ensuring successful market access. Central to this framework is the role of the Rapporteur, Co-Rapporteur, and the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA). This article serves as a comprehensive guide for professionals in Regulatory Affairs, Chemistry, Manufacturing and Controls (CMC), and Labelling teams who navigate these processes within the regulatory frameworks of the US, UK, and EU. Context Regulatory Affairs professionals play…

Lifecycle Management Under EU Rules: Variations, Renewals and PSURs Lifecycle Management Under EU Rules: Variations, Renewals and PSURs In the dynamic realm of pharmaceutical development and regulation, understanding the framework governing lifecycle management is pivotal for Regulatory Affairs (RA) professionals. This article explores the intricacies of managing variations, renewals, and periodic safety update reports (PSURs) within the European Union (EU) regulatory landscape, detailing the expectations set forth by the European Medicines Agency (EMA) and other relevant authorities. Our focus will encompass the regulatory context, documentation requirements, and best practices for efficient lifecycle management, particularly in the context of pharmacovigilance solutions….

National Competent Authorities vs EMA: Who Decides What? National Competent Authorities vs EMA: Who Decides What? Understanding the role of National Competent Authorities (NCAs) and the European Medicines Agency (EMA) is crucial for professionals engaged in regulatory affairs and compliance, particularly within the pharmaceutical and biotech sectors in the EU. This article aims to provide an in-depth explainer on the regulatory framework governing drug approval pathways in the EU, highlighting the responsibilities of both NCAs and the EMA, and drawing attention to the expectations set forth by various regulatory guidelines and authorities. Regulatory Affairs Context Regulatory affairs play a critical…

Common Issues That Trigger List of Questions (LoQ) in EU Reviews Common Issues That Trigger List of Questions (LoQ) in EU Reviews The regulatory landscape for pharmaceuticals in the European Union is complex and multifaceted, with criteria governing drug approval pathways established by regulations from the European Medicines Agency (EMA). Understanding the common issues that lead to a List of Questions (LoQ) during the review process is essential for Regulatory Affairs (RA) professionals. This article provides a comprehensive overview of the regulatory context, guidelines, and expected documentation practices, as well as practical strategies to enhance compliance and mitigate common deficiencies….

Bridging UK, EU and Global Strategies After EU-CTR and Brexit Bridging UK, EU and Global Strategies After EU-CTR and Brexit Context Regulatory Affairs (RA) plays a critical role in the pharmaceutical industry, ensuring compliance with various regulations governing drug development and approval. Following the implementation of the EU Clinical Trials Regulation (EU-CTR) and the UK’s exit from the EU (Brexit), it is essential for pharmaceutical companies to understand the shifting regulatory landscape across the UK, EU, and global markets. This article provides a structured overview of the regulatory frameworks and expectations from agencies such as the FDA, EMA, MHRA, and…